MD937C2 - Трансдермальная терапевтическая система для нанесения физостигмина и способ ее получения - Google Patents

Трансдермальная терапевтическая система для нанесения физостигмина и способ ее получения

Info

Publication number
MD937C2
MD937C2 MD94-0311A MD940311A MD937C2 MD 937 C2 MD937 C2 MD 937C2 MD 940311 A MD940311 A MD 940311A MD 937 C2 MD937 C2 MD 937C2
Authority
MD
Moldova
Prior art keywords
skin
therapeutic system
transdermal therapeutic
physostigmin
intermediate layer
Prior art date
Application number
MD94-0311A
Other languages
English (en)
Romanian (ro)
Other versions
MD940311A (en
MD937B2 (ru
Inventor
Lothar Deurer
Thomas Hille
Thomas Profitlich
Fritz Stanislaus
Kersten Walter
Original Assignee
Lts Lohmann Therapie-Systeme Gmbh & Co.Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lts Lohmann Therapie-Systeme Gmbh & Co.Kg filed Critical Lts Lohmann Therapie-Systeme Gmbh & Co.Kg
Publication of MD940311A publication Critical patent/MD940311A/xx
Publication of MD937B2 publication Critical patent/MD937B2/xx
Publication of MD937C2 publication Critical patent/MD937C2/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7038—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer
    • A61K9/7046—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds
    • A61K9/7053—Transdermal patches of the drug-in-adhesive type, i.e. comprising drug in the skin-adhesive layer the adhesive comprising macromolecular compounds obtained by reactions only involving carbon to carbon unsaturated bonds, e.g. polyvinyl, polyisobutylene, polystyrene
    • A61K9/7061—Polyacrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Materials For Medical Uses (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)

Abstract

Изобретение относится к трансдер-мальной терапевтической системе (ТТС) для введения физостигмина в качестве активного компонента, а также к способу ее получения.Трансдермальная терапевтическая система для нанесения физостигмина на кожу состоит из непроницаемого для активного вещества основы клей-кого промежуточного слоя, содер-жащего 40...90% полимерного мате-риала и 0,1...20% физостигминовой основы или его фармацевтически приемлемых солей, а также из защит-ного слоя, покрывающего промежу-точный слой, причем промежуточный слой содержит полимерный материал на основе акрилата и/или метакрилата и 0,1...40% пластификатора, имеющего гидроксильные группы с HLB-значе-нием от 1,1 до 12,0.Технический результат изобретения состоит в повышении прочности и времени фиксирования ТТС на коже и сохранении стабильности физостиг-мина в течение длительного времени.
MD94-0311A 1992-11-12 1994-07-26 Трансдермальная терапевтическая система для нанесения физостигмина и способ ее получения MD937C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE4238223A DE4238223C1 (de) 1992-11-12 1992-11-12 Transdermales therapeutisches System zur Verabreichung von Physostigmin an die Haut und Verfahren zu dessen Herstellung

Publications (3)

Publication Number Publication Date
MD940311A MD940311A (en) 1998-03-31
MD937B2 MD937B2 (ru) 1998-03-31
MD937C2 true MD937C2 (ru) 1999-01-31

Family

ID=6472735

Family Applications (1)

Application Number Title Priority Date Filing Date
MD94-0311A MD937C2 (ru) 1992-11-12 1994-07-26 Трансдермальная терапевтическая система для нанесения физостигмина и способ ее получения

Country Status (32)

Country Link
US (1) US5698216A (ru)
EP (1) EP0667774B1 (ru)
JP (1) JP3407073B2 (ru)
KR (1) KR100254573B1 (ru)
CN (1) CN1088457A (ru)
AT (1) ATE156356T1 (ru)
AU (1) AU684256B2 (ru)
CA (1) CA2147274C (ru)
CZ (1) CZ284008B6 (ru)
DE (2) DE4238223C1 (ru)
DK (1) DK0667774T3 (ru)
EE (1) EE03135B1 (ru)
EG (1) EG20527A (ru)
ES (1) ES2105334T3 (ru)
FI (1) FI952269L (ru)
GR (1) GR3024720T3 (ru)
HR (1) HRP931391B1 (ru)
HU (1) HUT72963A (ru)
IL (1) IL107547A (ru)
LT (1) LT3107B (ru)
LV (1) LV10749B (ru)
MD (1) MD937C2 (ru)
MY (1) MY111373A (ru)
NO (1) NO306760B1 (ru)
NZ (1) NZ257136A (ru)
PL (1) PL172999B1 (ru)
RU (1) RU2108812C1 (ru)
SI (1) SI9300589A (ru)
SK (1) SK280185B6 (ru)
WO (1) WO1994010999A1 (ru)
YU (1) YU71293A (ru)
ZA (1) ZA938413B (ru)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4446600A1 (de) * 1994-12-24 1996-06-27 Lohmann Therapie Syst Lts Transdermale Resorption von Wirkstoffen aus unterkühlten Schmelzen
DE19828273B4 (de) * 1998-06-25 2005-02-24 Lts Lohmann Therapie-Systeme Ag Transdermales therapeutisches System, enthaltend Hormone und Kristallisationsinhibitoren
DE19923551A1 (de) * 1999-05-21 2000-11-30 Lohmann Therapie Syst Lts Pharmazeutisches Präparat mit dem Wirkstoff Diamorphin und seine Verwendung in einem Verfahren zur Behandlung der Opiatsucht
DE10220230A1 (de) * 2002-05-06 2003-11-27 Sanol Arznei Schwarz Gmbh Verwendung von Rotigotine zur Behandlung des Restless Leg Syndroms
AT500143A1 (de) * 2004-04-22 2005-11-15 Sanochemia Pharmazeutika Ag Cholinesterase-inhibitoren in liposomen sowie deren herstellung und verwendung
ITMI20041628A1 (it) * 2004-08-06 2004-11-06 Bouty S P A Sistema terapeutico a rilascio controllato per uso topico transdermico

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921363A (en) * 1974-05-17 1975-11-25 Preston Metal & Roofing Prod Cross member with end connector
DE3528979A1 (de) * 1984-08-14 1986-02-27 State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona Arzneimittelfreigabesystem
DE3606892A1 (de) * 1985-03-05 1986-09-18 Ciba-Geigy Ag, Basel Pharmazeutische formulierungen und verfahren zur behandlung von gedaechtnisstoerungen
DE3843239C1 (ru) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (ru) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5350581A (en) * 1989-12-14 1994-09-27 Pharmetrix Corporation Method for manufacturing transdermal devices
NZ237241A (en) * 1990-03-02 1993-11-25 Pharmetrix Corp Method for increasing the storage stability of physostigmine
JP4355469B2 (ja) * 2002-03-08 2009-11-04 日本碍子株式会社 アルミナ担持担体、触媒体及びアルミナ担持担体の製造方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3921363A (en) * 1974-05-17 1975-11-25 Preston Metal & Roofing Prod Cross member with end connector
DE3528979A1 (de) * 1984-08-14 1986-02-27 State Of Israel Represented By The Prime Minister's Office Israel Institute For Biological Research, Ness-Ziona Arzneimittelfreigabesystem
DE3606892A1 (de) * 1985-03-05 1986-09-18 Ciba-Geigy Ag, Basel Pharmazeutische formulierungen und verfahren zur behandlung von gedaechtnisstoerungen
DE3843239C1 (ru) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
DE3843238C1 (ru) * 1988-12-22 1990-02-22 Lohmann Therapie Syst Lts
WO1991015176A1 (en) * 1990-04-06 1991-10-17 Pharmetrix Corporation Device and method for enhanced administration of physostigmine

Also Published As

Publication number Publication date
CA2147274C (en) 2005-12-13
SK59395A3 (en) 1996-05-08
LTIP1469A (en) 1994-06-15
AU5338594A (en) 1994-06-08
CN1088457A (zh) 1994-06-29
ATE156356T1 (de) 1997-08-15
HU9501390D0 (en) 1995-06-28
JPH08502986A (ja) 1996-04-02
CA2147274A1 (en) 1994-05-26
YU71293A (sh) 1996-07-24
IL107547A (en) 1996-12-05
SK280185B6 (sk) 1999-09-10
HRP931391B1 (en) 1999-12-31
MD940311A (en) 1998-03-31
CZ284008B6 (cs) 1998-07-15
ZA938413B (en) 1994-06-09
WO1994010999A1 (de) 1994-05-26
AU684256B2 (en) 1997-12-11
RU2108812C1 (ru) 1998-04-20
NO951864D0 (no) 1995-05-11
KR950703948A (ko) 1995-11-17
NZ257136A (en) 1996-07-26
EP0667774A1 (de) 1995-08-23
LV10749B (en) 1996-06-20
MD937B2 (ru) 1998-03-31
DE59307089D1 (de) 1997-09-11
FI952269A7 (fi) 1995-05-10
EP0667774B1 (de) 1997-08-06
US5698216A (en) 1997-12-16
LT3107B (en) 1994-12-27
ES2105334T3 (es) 1997-10-16
FI952269A0 (fi) 1995-05-10
LV10749A (lv) 1995-08-20
NO306760B1 (no) 1999-12-20
HUT72963A (en) 1996-06-28
NO951864L (no) 1995-05-11
HRP931391A2 (en) 1995-02-28
DK0667774T3 (da) 1998-03-23
JP3407073B2 (ja) 2003-05-19
SI9300589A (en) 1994-06-30
EG20527A (en) 1999-06-30
IL107547A0 (en) 1994-02-27
DE4238223C1 (de) 1994-05-26
GR3024720T3 (en) 1997-12-31
MY111373A (en) 1999-12-31
EE03135B1 (et) 1998-12-15
KR100254573B1 (ko) 2000-05-01
FI952269L (fi) 1995-05-10
CZ124495A3 (en) 1996-01-17
PL172999B1 (pl) 1998-01-30
PL308531A1 (en) 1995-08-21

Similar Documents

Publication Publication Date Title
YU47076B (sh) Postupak za izradu transdermalnog terapijskog sistema sa fizostigminom kao aktivnim sastojkom
MY109926A (en) Transdermal therapeutic system comprising galanthamine as active component
YU47077B (sh) Postupak za izradu transdermalnog terapijskog sistema sa fizostigminom kao aktivnim sastojkom
NO20001003D0 (no) Transdermalt terapeutisk system omfattende et trykksensitivt adhesivt reservoarsjikt og et unidireksjonalt elastisk dekksjikt
MD937C2 (ru) Трансдермальная терапевтическая система для нанесения физостигмина и способ ее получения
DE3770836D1 (de) Dermale und transdermale therapeutische systeme mit musterfoermig aufgetragener klebschicht, sowie verfahren zur dessen herstellung.
HUP9600147A1 (hu) Molsidomint vagy metabolitját tartalmazó transzdermális gyógyszerforma és eljárás annak előállítására

Legal Events

Date Code Title Description
FG4A Patent for invention issued
IF99 Valid patent on 19990615

Free format text: EXPIRES: 20140726